NL-OMON45258已完成不适用
A phase 1, open-label, non-randomized, 2-period, fixed sequence study to investigate the absorption, metabolism and excretion of [14C-PF-04965842] and to assess the absolute bioavailability and fraction absorbed of PF-04965842 in healthy male subjects using a 14C-microtracer approach. - A phase 1 study to investigate ADME and BA of [14C-PF-04965842].<br>
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer Inc.,
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •healthy male subjects
- •18 - 55 years, inclusive
- •BMI 17.5 - 30.5 kilograms/meter2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A phase 1, open-label, non-randomized, 2-period, fixed sequence study to investigate the absorption, distribution, metabolism and excretion of 14C-PF-06651600 and to assess the absolute bioavailability and fraction absorbed of PF-06651600 in healthy male participants using a 14C-microtracer approachNL-OMON48152Pfizer, Inc.6
已完成
不适用
A Phase 1, Open-Label, Non-Randomized, 2-Period, Fixed Sequence Study to Investigate the Absorption, Distribution, Metabolism and Excretion of [14c-Pf-06700841] and to Assess the Absolute Bioavailability and Fraction Absorbed of Pf-06700841 in Healthy Male Subjects using a 14C-Microtracer ApproachPsoriasis10003816NL-OMON45995Pfizer, Inc.6
已完成
不适用
A phase 1, open-label, randomized, 2-period, 2-sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants under fed conditiochronic myeloid leukemia10024324NL-OMON49458Pfizer, Inc.66
进行中（未招募）
1 期
A study investigating the safety, absorption and elimination of 2 formulations of Bosutinib, a drug in the treatment of chronic myeloid leukemia.EUCTR2020-002782-34-NLPfizer Inc.66
撤回
不适用
A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF 14C-PF-06835919 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-06835919 IN HEALTHY MALE PARTICIPANTS USING A 14C-MICROTRACER APPROACH.NL-OMON49734Pfizer Inc.6